Craft

BeyondSpring

Stock Price

$2.2

2024-10-29

Market Capitalization

$89.4 M

2024-10-29

Revenue

$1.4 M

FY, 2022

BeyondSpring Summary

Company Summary

Overview
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies. Its lead asset, plinabulin, is a selective immunomodulating microtubule-binding agent that is being developed as a direct anti-cancer agent in combination with docetaxel, in combination with immuno-oncology regimens, as well as for the prevention of chemotherapy-induced neutropenia.
Type
Public
Status
Active
Founded
2010
HQ
Florham Park, NJ, US | view all locations
Website
https://beyondspringpharma.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Lan Huang

    Lan Huang, Co-Founder, Chairman and Chief Executive Officer

  • June Lu

    June Lu, Chief Scientific Officer

    • Gordon Schooley

      Gordon Schooley, Chief Regulatory Officer

    • Sihai Xu

      Sihai Xu, Director

      Operating MetricsView all

      Patients Enrolled

      550

      Jun, 2016

      Phase I Trials Products

      2

      FY, 2019

      Phase III Trials Products

      3

      FY, 2019

      LocationsView all

      1 location detected

      • Florham Park, NJ HQ

        United States

        100 Campus Dr

      BeyondSpring Financials

      Summary Financials

      Revenue (FY, 2022)
      $1.4M
      Net income (FY, 2022)
      ($36.3M)
      Cash (FY, 2022)
      $34.4M
      EBIT (FY, 2022)
      ($37.2M)
      Enterprise value
      $59.9M

      Footer menu